Executive summary: key legal and evidentiary issues

• The Province of British Columbia, on behalf of all Canadian federal, provincial, and territorial governments, seeks to recover opioid-related health care costs from dozens of pharmaceutical manufacturers and distributors for conduct from 1996 onward.

• Manufacturer defendants are alleged to have negligently designed opioid products and aggressively misrepresented the risks and benefits of opioids, causing an escalation in prescriptions and a resulting opioid epidemic.

• Distributor defendants allegedly delivered opioids in quantities they knew or should have known exceeded any legitimate market and failed to warn of risks and dangers.

• Jurisdictional challenges by LPG, Jean Coutu, and Pro Doc were dismissed, and the Court certified the action as a class proceeding under the Class Proceedings Act, finding that a single class proceeding is preferable to 13 stand-alone actions.

• In the subsequent 2026 decision on document production, the Court accepted the Province's position that the ORA trial should proceed in three stages, significantly narrowing the scope of discoverable documents at Stage 1 to only four of the 44 certified common issues.

• All three defence document production applications were largely dismissed as overbroad and premature, except for limited production related to the Province's unjust enrichment claims.

The Province's claims and the opioid epidemic

In British Columbia v. Apotex Inc., His Majesty the King in Right of the Province of British Columbia brought an unprecedented class proceeding against dozens of pharmaceutical manufacturers, wholesalers, and distributors of opioid products in Canada. The Province filed the action on behalf of itself and all federal, provincial, and territorial governments, seeking to recover health care, pharmaceutical, and treatment costs related to prescription opioids from 1996 onward. The defendant group included major entities such as Apotex Inc., Bristol-Myers Squibb, Janssen Inc., Johnson & Johnson, Teva Canada, Sandoz Canada, Purdue Pharma, McKesson Corporation, Kohl & Frisch Limited, Shoppers Drug Mart, and many others. The Province alleged that a significant increase in opioid prescriptions beginning in the late 1990s, peaking between 2011 and 2016, contributed to an opioid epidemic of addiction, overdose, and death across all Canadian jurisdictions.

The allegations against the defendants

The Province divided the defendants into two principal groups. The Manufacturer Defendants allegedly marketed and promoted opioid products in Canada as being less addictive than was actually known and for conditions the manufacturers knew the drugs were not effective in treating. The Generic Manufacturer Defendants, including Apotex, Pharmascience, Pro Doc, Sandoz, and Teva, were alleged to have endorsed and promulgated misrepresentations made by brand name manufacturers and to have deliberately manufactured and sold their generic versions without regard for risks to public health. The Distributor Defendants, including McKesson, Kohl & Frisch, Jean Coutu, and others, allegedly delivered opioid products to pharmacies and hospitals in quantities that exceeded any legitimate market, ignoring suspicious sales volumes and patterns, and failing to warn end users of known risks.

The legislative framework: the ORA and health care costs recovery

Central to the Province's case was the Opioid Damages and Health Care Costs Recovery Act (ORA), S.B.C. 2018, c. 35. This legislation, similar to the earlier Tobacco Damages Recovery Act used in tobacco litigation, created a statutory cause of action enabling the Province to recover opioid-related health care costs. Notably, section 11 of the ORA uniquely permitted the bringing of "multi-Crown" class proceedings, allowing the Province to sue on behalf of other Canadian governments. The causes of action advanced included statutory claims under the ORA based on negligent failure to warn, negligent design, negligent and fraudulent misrepresentation, breach of the Competition Act, breach of the Food and Drugs Act, unjust enrichment, and allegations of common design among the defendants.

The certification decision (2025 BCSC 92)

On January 22, 2025, Justice Brundrett released the certification judgment. The Court first addressed jurisdictional challenges raised by LPG Inventory Solutions, Jean Coutu, and Pro Doc. LPG submitted that the Court lacked subject matter competence because the claims against it arose in Ontario. Jean Coutu and Pro Doc submitted that other jurisdictions offered a more appropriate forum for the resolution of the Province's claims. Justice Brundrett dismissed all jurisdictional challenges, finding that legislative restrictions did not prevent the exercise of the Court's jurisdiction and that no alternative forum would be fairer or more efficient.
Turning to certification, the Court considered the five criteria under section 4(1) of the Class Proceedings Act. The defendants vigorously opposed certification, arguing that differences among the defendants, their products, the time-frames of their activities, and the jurisdictions in which they operated meant individual issues would overwhelm any common issues. They further argued that Canadian governments, as the plaintiff class, did not need the class action mechanism for access to justice. Despite these objections, Justice Brundrett found that all certification requirements were met. The Court identified sufficient common issues across the class, including questions about the effects of opioids, the manufacturers' alleged misrepresentations, the defendants' knowledge, common design, unjust enrichment, and breaches of the Competition Act and the ORA. The Court concluded that a class proceeding was the preferable procedure, finding it "a far better option than the alternatives from a practical cost-benefit approach," compared with the prospect of running 13 nearly identical stand-alone actions across different provincial and territorial jurisdictions. The Province was appointed as the representative plaintiff, and 44 common issues were certified.

The document production decision (2026 BCSC 209)

Following certification, the case proceeded to the pre-trial document disclosure phase, which was the subject of the second decision rendered by Justice Ross on February 9, 2026. The case was set for an 80-day trial commencing February 22, 2028, and the defendants noted that the claims could range up to $91 billion. Three applications were before the Court: (1) the Manufacturer Defendants' (TR Defendants') application for document production from the Province; (2) the McKesson Defendants' application on behalf of the Distributor Defendants for document production from the Province; and (3) the Janssen Defendants' application for document production from the class members (the other governments).
A critical dispute concerned the Province's position that the ORA prescribes a trial proceeding in three stages. The Province argued that at Stage 1, only four of the 44 certified common issues needed to be addressed, namely whether opioid products can cause disease, what those diseases are, whether the manufacturers' misrepresentations caused an increase in opioid prescriptions, and the equivalent ORA-based causation question. The defendants resisted this staging approach, arguing that all 44 common issues should be litigated together, which would justify their expansive document requests. The Court accepted the Province's staging position, finding that the defendants' document requests as they related to the ORA claims were not material or relevant at Stage 1.
The Court also found all three defence applications to be overbroad. The TR Defendants' Scott Schedule alone was 74 pages long, listing over 140 types of requested documents, while the Janssen application for class member documents spanned 34 pages with more than 230 categories. The McKesson Defendants' application for document production from the Province was dismissed on the same grounds, with the Court also rejecting the distributors' argument that the claims against them raised a novel duty of care, finding instead that it is well established in Canadian law that distributors owe a duty to warn of inherently dangerous products.

Ruling and outcome

In the certification decision, the Province of British Columbia was successful in having the action certified as a class proceeding with 44 common issues, having all jurisdictional challenges dismissed, and being appointed as the representative plaintiff on behalf of all Canadian federal, provincial, and territorial governments. In the subsequent document production decision, the Court largely ruled in favour of the Province. The TR Defendants' application was dismissed except for limited production related to the unjust enrichment claims, specifically documents related to the Province's purchase of opioid medicines and documents relating to circumstances where opioid use was considered not medically necessary or inappropriate. The McKesson Defendants' application was dismissed in its entirety, and the Janssen Defendants' application for class member documents was also dismissed, with the Court finding that such production was not warranted at this stage and may only become relevant at the individual claims stage. No exact monetary amount was awarded or ordered at this stage of the proceedings, as the litigation remains in the pre-trial phase with an 80-day common issues trial set for February 2028. The certification decision itself is currently under appeal by the defendants.